Bain Capital Life Sciences Fund III, L.P.
Raised
Pre-open
Investors
—
Min Invest
None stated
Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.
AltStreet Analysis
·Generated from EDGAR primary sources
Bain Capital Life Sciences Fund III, L.P. is a Delaware pooled investment fund formed by Bain Capital, filed under Rule 506(b) with a concurrent 3(c) Investment Company Act exclusion. The Form D was filed as an original (non-amendment) pre-open filing with no first sale date, total amount sold, or investor count disclosed — consistent with an early-stage filing ahead of fund closing. No minimum investment is stated on the form, and no parent platform or sibling entities are currently matched in the database.
This filing fits the standard profile of an institutional private equity/venture-style pooled investment fund raising under the 506(b) exemption paired with a 3(c) fund exclusion, a common combination for life sciences-focused investment vehicles. With raise amount, investor count, and minimum investment all undisclosed at this pre-open stage, the filing provides limited comparative data relative to typical alternative investment offerings in this category.
Data Flags
EDGAR Filing Data
Form D — Primary Source
View on SEC.govFilings on Record
Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.
In the Terminal
Filing events
0
none on file
Critical / warning
0 / 0
0 watch · 0 info
Statements extracted
0
none on file
NAV prints
0
none on file
Offering chains
1
pre_sale
Fund family Part of the Bain Capital Life Sciences Fund family: 4 vehicles across 3 generations · adviser of record Bain Capital Private Equity, LP · full family and the filing behind each link in the terminal
Investor
- The full fund family and any related vehicles (parallel, feeder, successor, sibling series) with the filing that shows each link
- 1 offering timeline: velocity, share raised, first-sale lag, stalled flags
Pro
- This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
- The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV
Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…
Adviser of Record (Form ADV)
CRD 145653 · SEC-registered adviser · lists this fund on Schedule D 7.B.(1) as a private equity fund
Auditor named on Form ADV: PricewaterhouseCoopers LLP · PCAOB-registered per the adviser
From the adviser's Form ADV as loaded from the SEC bulk data, joined on this issuer's Form D file number. Fund-level figures and the adviser's full fund roster are in the terminal.
Related Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
Adam Koppel
Executive Officer · Boston, MA
Jeffrey Schwartz
Executive Officer · Boston, MA
Placement Agents and Sales Compensation (Form D)
Who the issuer reported paying to sell the securities (Form D Item 12), with the FINRA registration number the filer gave. Source: SEC.gov.
Bain Capital Distributors, LLCCRD 175456 on BrokerCheck
Associated broker-dealer: None · Boston, MA · Soliciting in all states
Questions About Bain Capital Life Sciences Fund III, L.P.
Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.
What is Bain Capital Life Sciences Fund III, L.P.?
Bain Capital Life Sciences Fund III, L.P. is a Delaware limited partnership that filed a Form D with the SEC on August 3, 2021 as a private equity fund. The filing claims Rule 506(b), Section 3(c), Section 3(c)(7) for an offering of pooled investment fund interests.
Is Bain Capital Life Sciences Fund III, L.P. legit?
AltStreet does not rate legitimacy; it reports the public record. Bain Capital Life Sciences Fund III, L.P. filed a Form D with the SEC on August 3, 2021 claiming Rule 506(b), Section 3(c), Section 3(c)(7). A Form D is a notice of an exempt offering, not a review or approval of it. No sales had been reported as of that notice. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.
Is Bain Capital Life Sciences Fund III, L.P. registered with or approved by the SEC?
No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Bain Capital Life Sciences Fund III, L.P. claimed Rule 506(b), Section 3(c), Section 3(c)(7) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.
How much has Bain Capital Life Sciences Fund III, L.P. raised?
Bain Capital Life Sciences Fund III, L.P. reported that the first sale had not yet occurred as of the Form D filed August 3, 2021, so no amount sold or investor count is on file. The total offering amount is listed as indefinite.
Who can invest in Bain Capital Life Sciences Fund III, L.P.?
The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. Because the fund also relies on Section 3(c)(7), each investor must be a qualified purchaser, generally an individual with at least $5 million in investments. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated.
What is the minimum investment in Bain Capital Life Sciences Fund III, L.P.?
The Form D lists the minimum investment as $0, which means the issuer did not state a minimum on the form. The offering documents, not the Form D, set the actual subscription terms.
Who is selling Bain Capital Life Sciences Fund III, L.P. and how are they paid?
The Form D names Bain Capital Distributors, LLC (CRD 175456), associated with None as the recipient of sales compensation soliciting in all states.
Who is behind Bain Capital Life Sciences Fund III, L.P.?
The Form D lists 2 related persons: Adam Koppel, executive officer; Jeffrey Schwartz, executive officer. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.
Where is Bain Capital Life Sciences Fund III, L.P. located?
The issuer's address on its SEC filings is 200 Clarendon St, Boston, MA 02116. Its phone number of record is 16175162000. It is organized under the laws of Delaware.
How long is the Bain Capital Life Sciences Fund III, L.P. offering open?
The issuer indicated that the offering is not intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open, and no amendment is on record yet.
How large is Bain Capital Life Sciences Fund III, L.P.?
The issuer declined to disclose its revenue range on the Form D, which the form permits.
Is this your company or fund?
Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.
Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.